Adilia Hormigo, MD, PhD
- ASSOCIATE PROFESSOR | Neurology
- ASSOCIATE PROFESSOR | Neurosurgery
- ASSOCIATE PROFESSOR | Medicine
Research Topics:Anti-Tumor Therapy, Brain, Cancer, Tumorigenesis
Adilia Hormigo, MD, PhD is Director of the Neuro-Oncology Program for The Mount Sinai Hospital and the Mount Sinai Health System, and Associate Professor in the Department of Neurology with a secondary appointment in the Departments of Medicine, and Neurosurgery. Dr. Hormigo is a neuro-oncologist specializing in the care of patients with primary brain tumors, CNS metastases, and the neurological complications of cancer and its treatment. She employs a multidisciplinary team approach to ensure that patients receive compassionate, comprehensive care.
Dr. Hormigo completed a residency in Neurology in Portugal, at the University Hospital of Lisbon Medical School and Portuguese Oncological Institute, as well as at New York Presbyterian-Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center where she completed both research and clinical neuro-oncology fellowships under Jerome B. Posner and served as Assistant Professor of Neurology and Assistant Member. There she trained a number of fellows, many of whom are now junior faculty in leading programs of neuro-oncology in the country and abroad. Dr. Hormigo obtained her MD with honors from the University of Lisbon Medical School in Portugal, and her PhD from New York University.
Prior to joining the Mount Sinai team, Dr. Hormigo served as Associate Professor in the Departments of Neurology, Oncology, Neurosurgery, and the Center for Translational Neuromedicine at the University of Rochester Medical Center. Her translational research has focused on studying tumor microenvironment, developing biomarkers and personalized new treatments for patients with brain tumors. Her goal is to achieve the highest level of patient care and clinical excellence for the neuro-oncology program. She sees patients at the Ruttenberg Treatment Center of the Tisch Cancer Institute.
Neurology, American Board of Psychiatry and Neurology
- Brain Metastasis
- Brain Tumors
- Lumbar Puncture
- Paraneoplastic Syndromes, Central Nervous System
- Primary Central Nervous System Lymphoma
- Spinal Cord Tumors
Research Fellow, Memorial Sloan-Kettering Cancer Center
PhD, New York University
MD, PhD, Faculdade De Medicina DA Universidade De Lisboa
Internship, Neurology, Universidade De Lisboa
Residency, Neurology, Universidade De Lisboa
Internship, Internal Medicine, New York Presbyterian - Weill Cornell Medical Center
Residency, Neurology, New York Presbyterian - Weill Cornell Medical Center
Fellowship, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center
Advanced Techniques in Molecular Neuroscience
Excellence in Teaching Award for the Neurology Clerkship
Second UCB Neurology Award
- N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme
The purpose of this research is to study any good and bad effects of combining bevacizumab with another chemotherapy drug called TRC105, and comparing the combination to the usual approach which is chemotherapy with bevacizumab alone. TRC 105 is not approved by the FDA f...
Iwamoto FM, Hormigo A. Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Frontiers in oncology 2014; 4.
Fisher R, Hormigo A. Adjuvant therapy for patients with newly diagnosed glioblastoma. In: Glioblastoma Multiforme: Neurological Symptoms, Therapeutic Management, and Outcome. Hauppauge, NY, Nova Science Publishers;.
Ding BS, James D, Iyer R, Falciatori I, Hambardzumyan D, Wang S, Butler JM, Rabbany SY, Hormigo A. Prominin 1/CD133 endothelium sustains growth of proneural glioma. PloS one 2013; 8(4).
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology 2013 Feb; 15(2).
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro-oncology 2011 Nov; 13(11).
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. Journal of neuro-oncology 2011 Dec; 105(3).
Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Annals of neurology 2011 Jul; 70(1).
Pentsova E, Liu A, Rosenblum M, O'Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. Journal of neuro-oncology 2012 Jan; 106(1).
Hormigo A, Ding BS, Rafii S. A target for antiangiogenic therapy: vascular endothelium derived from glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 2011 Mar; 108(11).
Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. Journal of neuro-oncology 2008 Jul; 88(3).
Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. Journal of neuro-oncology 2007 Nov; 85(2).
Hormigo A, Gutin PH, Rafii S. Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer cell 2007 Jan; 11(1).
Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Oct; 12(19).
Deangelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Seminars in oncology 2004 Oct; 31(5).
Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. British journal of haematology 2004 Jul; 126(2).
Hormigo A, Liberato B, Lis E, DeAngelis LM. Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities. Archives of neurology 2004 Mar; 61(3).
Hormigo A, DeAngelis LM. Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clinical lymphoma 2003 Jun; 4(1).
Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Aug; 27(23).
Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Oct; 20(19).